MCID: JPN002
MIFTS: 49

Japanese Encephalitis malady

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Japanese Encephalitis

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 12DISEASES, 51Orphanet, 2CDC, 65UMLS, 47Novoseek, 36MeSH, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Japanese Encephalitis:

Name: Japanese Encephalitis 10 45 12 51 2 65
Je 45 2
Japanese B Encephalitis 10
 
Encephalitis, Japanese 36
Encephalitis Japanese 47

Characteristics:

Orphanet epidemiological data:

51
japanese encephalitis:
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology10 DOID:10844
ICD1027 A83.0
ICD9CM29 062.0
MeSH36 D004672
NCIt42 C34577
Orphanet51 79139
ICD10 via Orphanet28 A83.0
MESH via Orphanet37 D004672
UMLS via Orphanet66 C0014057
UMLS65 C0014057

Summaries for Japanese Encephalitis

About this section
CDC:2 Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia and the western Pacific. For most travelers to Asia, the risk for JE is very low but varies based on destination, duration of travel, season, and activities. JE virus is maintained in a cycle involving mosquitoes and vertebrate hosts, mainly pigs and wading birds. Humans can be infected when bitten by an infected mosquito. Most human infections are asymptomatic or result in only mild symptoms. However, a small percentage of infected persons develop inflammation of the brain (encephalitis), with symptoms including sudden onset of headache, high fever, disorientation, coma, tremors and convulsions. About 1 in 4 cases are fatal. There is no specific treatment for JE. Patient management focuses on supportive care and management of complications. Steps to prevent JE include using personal protective measures to prevent mosquito bites and vaccination.

MalaCards based summary: Japanese Encephalitis, also known as je, is related to motion sickness and viral hepatitis, and has symptoms including headache, high fever and neck stiffness. An important gene associated with Japanese Encephalitis is CLEC4M (C-Type Lectin Domain Family 4 Member M), and among its related pathways are Prion diseases and Dendritic Cells Developmental Lineage Pathway. Affiliated tissues include brain, brain and heart, and related mouse phenotypes are homeostasis/metabolism and hematopoietic system.

Disease Ontology:10 A viral infectious disease that results in infection located in brain, has material basis in Japanese encephalitis virus, which is transmitted by Culex tritaeniorhynchus mosquito bite. The infection has symptom headache, has symptom high fever, has symptom neck stiffness, has symptom stupor, has symptom disorientation, has symptom coma, has symptom tremors, has symptom convulsions, and has symptom spastic paralysis.

Wikipedia:68 Japanese encephalitis (JE), formerly known as Japanese B encephalitis to distinguish it from Economo\'s... more...

Related Diseases for Japanese Encephalitis

About this section

Graphical network of the top 20 diseases related to Japanese Encephalitis:



Diseases related to japanese encephalitis

Symptoms for Japanese Encephalitis

About this section

Symptoms:

 10 (show all 9)
  • headache
  • high fever
  • neck stiffness
  • stupor
  • disorientation
  • coma
  • tremors
  • convulsions
  • spastic paralysis

Drugs & Therapeutics for Japanese Encephalitis

About this section

Drugs for Japanese Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Phase 4
2ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 14477
3AntibodiesPhase 4, Phase 3, Phase 2, Phase 14477
4VaccinesPhase 4, Phase 3, Phase 2, Phase 16085
5Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
6
Aluminum hydroxideapprovedPhase 3178
Synonyms:
Al(OH)3
Aluminiumhydroxid
 
Aluminum Hydroxide
Aluminum hydroxide
Dermadrox
7Pharmaceutical SolutionsPhase 37004
8
LactitolPhase 3320585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
9Heptavalent Pneumococcal Conjugate VaccinePhase 3440
10Protective AgentsPhase 35651
11Insect RepellentsPhase 32
12
NeomycinapprovedPhase 1, Phase 2421404-04-28378
Synonyms:
(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
11025-81-3
119-04-0
1393-86-8
1404-04-2
1405-10-3 (sulfate (salt))
4-18-00-07476 (Beilstein Handbook Reference)
72131_FLUKA
AB00443887
AC1L1QVH
Actilin
Actiline
Antibiotic 10676
Antibiotic produced by Streptomyces decaris. Neomycin B
Antibiotique
BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG
BDG-(1-4)NEB-(5-1)RIB-(3-1)NED
BPBio1_000326
BRN 0101621
BSPBio_000296
C01737
C23H46N6O13
C25H50N6O13
CCRIS 5462
CHEBI:7508
CID8378
Caswell No. 595
D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy
D05140
DB00452
DB00994
EINECS 204-292-2
EINECS 215-766-3
EPA Pesticide Chemical Code 006303
Endomixin
Enterfram
Fradiomycin
Fradiomycin B
Fradiomycinum
Framicetina
Framicetina [INN-Spanish]
Framycetin
Framycetin (INN)
Framycetin [INN:BAN:DCF]
Framycetine
Framycetine [INN-French]
Framycetinum
Framycetinum [INN-Latin]
Framygen
 
Fraquinol
HMS2089P15
HSDB 3242
LS-96091
LS-96095
MolPort-003-938-736
Myacine
Myacyne
Mycifradin
Myciguent
N1142_SIGMA
NCGC00179612-01
NEOMYCIN AND POLYMYXIN B SULFATES
NEOMYCIN B
NEOMYCIN SULFATE
NMY
Neo-Fradin
Neo-Rx
Neo-fradin
Neobiotic
Neobrettin
Neolate
Neomas
Neomcin
Neomicina
Neomicina [DCIT]
Neomin
Neomycin B Sulfate
Neomycin B sulfate
Neomycin Sulfate
Neomycin Sulphate
Neomycin solution
Neomycine
Neomycine [INN-French]
Neomycinum
Neomycinum [INN-Latin]
Nivemycin
PIMAVECORT
Prestwick3_000158
ST075177
Soframycin
Soframycin Ophthalmic
Soframycine
Theraplusplus Plus
Tuttomycin
UNII-4BOC774388
UNII-I16QD7X297
USAF CB-19
VONAMYCIN
Vonamycin powder V
neomycin
13
RibavirinapprovedPhase 294836791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
Ibavyr
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
Moderiba
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
 
NSC 163039
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribasphere Ribapak
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
14Rho(D) Immune GlobulinPhase 2206
15Immunoglobulins, IntravenousPhase 2211

Interventional clinical trials:

(show top 50)    (show all 74)
idNameStatusNCT IDPhase
1A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2CompletedNCT01656200Phase 4
2This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationCompletedNCT01158599Phase 4
3Post-licensure Safety Study of IMOJEV® in ThailandCompletedNCT01981967Phase 4
4Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAXCompletedNCT02526550Phase 4
56-year Antibody Check After Third Vaccination Against Japanese EncephalitisCompletedNCT02039440Phase 4
6Lot-to-lot Consistency Trial of JE Live Attenuated SA 14-14-2 VaccineCompletedNCT01567865Phase 4
7Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE VaccineCompletedNCT01815073Phase 4
8Immunogenicity of SA 14-14-2 JE VaccineCompletedNCT01635816Phase 4
9Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis VaccineinjRecruitingNCT02532569Phase 4
10Immunogenicity of Co-administration of Measles and Japanese Encephalitis VaccinesRecruitingNCT02643433Phase 4
11Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster DoseActive, not recruitingNCT02514746Phase 4
12Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis VaccineEnrolling by invitationNCT01398540Phase 4
13Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in ChildrenNot yet recruitingNCT01954810Phase 4
14Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in ToddlersCompletedNCT01396512Phase 3
15A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and ToddlersCompletedNCT01092507Phase 3
16Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 3
17Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the PhilippinesCompletedNCT00735644Phase 3
18Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles VaccineCompletedNCT00249769Phase 3
19Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in ToddlersCompletedNCT01001988Phase 3
20Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles VaccineCompletedNCT00412516Phase 3
21Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult SubjectsCompletedNCT01662440Phase 3
22A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 3
23Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese EncephalitisCompletedNCT01386827Phase 3
24Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51CompletedNCT00596102Phase 3
25Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationCompletedNCT01041573Phase 3
26Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of AgeCompletedNCT00463684Phase 3
27Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai ChildrenCompletedNCT01408537Phase 3
28Safety and Tolerability of the Japanese Encephalitis Vaccine IC51CompletedNCT00605085Phase 3
29Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE VaccineCompletedNCT00463476Phase 3
30Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00595790Phase 3
31Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595270Phase 3
32Immunogenicity Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00604708Phase 3
33A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAXCompletedNCT00314145Phase 3
34Study of a Booster Dose of IMOJEV® Vaccine One Year After Primary Immunization in Healthy Children in South KoreaCompletedNCT01900444Phase 3
35Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.CompletedNCT00314132Phase 3
36Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryCompletedNCT01296360Phase 3
37Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00595465Phase 3
38Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00594958Phase 3
39Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440CompletedNCT00596271Phase 3
40Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595309Phase 3
41Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingCompletedNCT00776230Phase 3
42Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic CountriesCompletedNCT01047839Phase 3
43Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyCompletedNCT01246479Phase 3
44Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in KoreaCompletedNCT01150942Phase 3
45Novartis Vaccine and Diagnostics Carriage TrialCompletedNCT01214850Phase 3
46Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDRRecruitingNCT00938379Phase 3
47Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CVActive, not recruitingNCT01190228Phase 3
48A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese InfantsActive, not recruitingNCT02367664Phase 3
49Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy SubjectsActive, not recruitingNCT02492165Phase 3
50A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.Active, not recruitingNCT02545517Phase 3

Search NIH Clinical Center for Japanese Encephalitis


Cochrane evidence based reviews: encephalitis, japanese

Genetic Tests for Japanese Encephalitis

About this section

Anatomical Context for Japanese Encephalitis

About this section

MalaCards organs/tissues related to Japanese Encephalitis:

33
Brain, Heart, Bone, T cells, Breast, Liver, Colon

FMA organs/tissues related to Japanese Encephalitis:

16
Brain

Animal Models for Japanese Encephalitis or affiliated genes

About this section

MGI Mouse Phenotypes related to Japanese Encephalitis:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053767.0CLEC4G, CLEC4M, CXCL10, DDX58, HELLS, IFNB1
2MP:00053976.9CLEC4G, CLEC4M, CXCL10, DDX58, HELLS, IFNB1
3MP:00053876.1CLEC4G, CLEC4M, CXCL10, DDX58, HELLS, IFNB1

Publications for Japanese Encephalitis

About this section

Articles related to Japanese Encephalitis:

(show top 50)    (show all 604)
idTitleAuthorsYear
1
Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat. (26392152)
2015
2
What is known about the subjective needs of people with behavioural variant frontotemporal dementia? A scoping review. (25827780)
2015
3
c-Fos is involved in inhibition of human bladder carcinoma T24 cells by Brazilin. (25865820)
2015
4
Double filtration plasmapheresis in the treatment of pancreatitis due to severe hypertriglyceridemia. (26350817)
2015
5
Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. (24262510)
2014
6
Nodular hidradenoma of the scalp: A cytomorphological evaluation on fine needle aspiration cytology. (25382530)
2014
7
LRRC4 haplotypes are associated with pituitary adenoma in a Chinese population. (24563334)
2014
8
Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. (23412344)
2013
9
Focus on technique: one-stage implant-based breast reconstruction. (23096993)
2012
10
Narcolepsy: neural mechanisms of sleepiness and cataplexy. (22956821)
2012
11
The E3 ubiquitin ligase Mahogunin ubiquitinates the melanocortin 2 receptor. (21862608)
2011
12
Development and validation of a standardized ELISA for the detection of soluble Fc-epsilon-RI in human serum. (21903095)
2011
13
An II_BI+ phosphorylation inhibitor induces heme oxygenase-1(HO-1) expression through the activation of reactive oxygen species (ROS)-Nrf2-ARE signaling and ROS-PI3K/Akt signaling in an NF-I_B-independent mechanism. (21620964)
2011
14
S100A11 mediates hypoxia-induced mitogenic factor (HIMF)-induced smooth muscle cell migration, vesicular exocytosis, and nuclear activation. (21139050)
2011
15
Thoracoscopic treatment of chylothorax after patch repair of congenital diaphragmatic hernia. (20713234)
2010
16
Proteomic analysis of enriched lysosomes at early phase of camptothecin-induced apoptosis in human U-937 cells. (19393779)
2009
17
Estimation of benchmark dose for bone damage and renal dysfunction in a Chinese male population occupationally exposed to lead. (18567606)
2008
18
Neuroretinitis, a great mimicker. (19893649)
2008
19
Association between genetic polymorphism of GSTT1 and depression score in individuals chronically exposed to natural sour gas. (18325667)
2008
20
Analysis of obstetric complications and uterine connective tissue in tenascin-X-deficient humans and mice. (18335242)
2008
21
SIRT1 is involved in glucocorticoid-mediated control of uncoupling protein-3 gene transcription. (17884810)
2007
22
Functional interaction between Rh proteins and the spectrin-based skeleton in erythroid and epithelial cells. (16580865)
2006
23
Aplasia of the dorsal pancreas and choledochal cyst. (16474976)
2006
24
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. (16307829)
2006
25
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. (16267030)
2005
26
Brain natriuretic peptide and acute coronary syndrome. (15827538)
2005
27
Calcium activation of ryanodine receptor channels--reconciling RyR gating models with tetrameric channel structure. (16260840)
2005
28
Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression. (15210847)
2004
29
Esophageal tuberculosis abscess: an unusual cause of dysphagia. (12060051)
2002
30
Spontaneous remission of spasms in West syndrome--implications of viral infection. (11701282)
2001
31
TFIIH action in transcription initiation and promoter escape requires distinct regions of downstream promoter DNA. (11331764)
2001
32
Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. (11279663)
2001
33
Effects of filtration and gamma radiation on the accumulation of RANTES and transforming growth factor-beta1 in apheresis platelet concentrates during storage. (10336000)
1999
34
MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. (10537276)
1999
35
Psychiatric comorbidity in patients with burning mouth syndrome. (9625229)
1998
36
Thrombin receptor overexpression in malignant and physiological invasion processes. (9701242)
1998
37
Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation. (9574537)
1998
38
Transcription factor decoy for nuclear factor-kappaB inhibits tumor necrosis factor-alpha-induced expression of interleukin-6 and intracellular adhesion molecule-1 in endothelial cells. (9794740)
1998
39
Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. (12795808)
1997
40
Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. (8608226)
1996
41
Chondroid syringoma. A rare occurrence in the hallux. (8394420)
1993
42
Distribution of type VIII collagen in tissues: an immunohistochemical study. (2376131)
1990
43
The mammalian analogue of the yeast PRP8 splicing protein is present in the U4/5/6 small nuclear ribonucleoprotein particle and the spliceosome. (2479028)
1989
44
Bubonic plague in nineteenth-century China. (11620272)
1988
45
Aortopulmonary window, aortic origin of the right pulmonary artery, and interrupted aortic arch: detection by two-dimensional and color Doppler echocardiography in an infant. (3774581)
1986
46
Unilateral night blindness with normal fundus. (6496621)
1984
47
Use of hypertonic-barium mixtures in the diagnosis of the dumping syndrome. (942115)
1976
48
Reconstruction of the external genitalia in exstrophy of the bladder: preliminary communication. (4275413)
1974
49
50

Variations for Japanese Encephalitis

About this section

Expression for genes affiliated with Japanese Encephalitis

About this section
Search GEO for disease gene expression data for Japanese Encephalitis.

Pathways for genes affiliated with Japanese Encephalitis

About this section

Pathways related to Japanese Encephalitis according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.4CXCL10, SOD1
29.3CD209, IFNB1
39.0CD209, CLEC4M, IFNB1
4
Show member pathways
8.7CXCL10, DDX58, IFNB1
58.7CXCL10, IFNB1, ISG15
6
Show member pathways
8.6DDX58, IFNB1, ISG15
7
Show member pathways
8.2CXCL10, DDX58, IFNB1, ISG15
8
Show member pathways
8.0CD209, CLEC4M, CXCL10, DDX58, IFNB1

GO Terms for genes affiliated with Japanese Encephalitis

About this section

Biological processes related to Japanese Encephalitis according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1intracellular transport of virusGO:007573310.2CD209, CLEC4M
2endocytosisGO:000689710.2CD209, CLEC4M
3regulation of protein kinase activityGO:004585910.0CXCL10, SOD1
4response to virusGO:00096159.6DDX58, IFNB1
5adaptive immune responseGO:00022509.3CD209, CLEC4M, IFNB1
6defense response to bacteriumGO:00427429.0IFNB1, ISG15
7innate immune responseGO:00450878.8CD209, CLEC4M, DDX58, ISG15
8defense response to virusGO:00516078.4CXCL10, IFNB1, ISG15

Molecular functions related to Japanese Encephalitis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1virus receptor activityGO:00016189.8CD209, CLEC4M

Sources for Japanese Encephalitis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet